Alseres Pharmaceuticals, Inc. Reports 2007 Financial Results and Provides Company ...(ical Surgeons (AANS) April 2007; -- A...)

-- American Spinal Injury Association (ASIA), June 2007;

-- World Spine, July 2007;

-- Congress of Neurological Surgeons, September 2007; and

-- North American Spine Society, October 2007

Advanced the Molecular Imaging Program.

-- In July 2007, Alseres completed a study with our collaborators that

optimized ALTROPANE's image acquisition protocol. We believe the

optimized protocol will enhance ALTROPANE's use once commercialized.

-- After a series of discussions with the FDA and our expert advisors, our

POET-2 program was designed as a two-part Phase III program using the

optimized ALTROPANE image acquisition protocol. The first part of the

program was initiated in December 2007 in a multi-center clinical study

in subjects to acquire a set of ALTROPANE images to train the expert

readers. The second part involves two concurrent, replicate, multi

center Phase III trials. These two concurrent trials will be initiated

once final agreement on the design of the two trials is reached with

the FDA.

-- Data from a study to evaluate the Test/Re-test reliability of ALTROPANE

in Parkinson disease patients were presented at Movement Disorder

Society's 11th International Congress of Parkinson's Disease and

Movement Disorders in June 2007. The data demonstrated that ALTROPANE

uptake is reduced in Parkinson's Disease patients with moderate PD and

has excellent test/re-test reliability.

-- We advanced partnering discussions for our Molecular Imaging Program

the focus of which was the completion of the Phase III clinical

program, development of the product in Dementia with Lewy Bodies,

development of the product in Europe, ultimately the launch and

commercialization of ALTROPANE and product family life cycle managemen
'/>"/>